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The South African National Prevention of Mother-to-Child Transmission of HIV programme has resulted in significant 
reductions in vertical transmission, but new infant HIV infections continue to occur. We present two cases of HIV seroconversion 
during late pregnancy, demonstrating the limitations of the current programme. These could be mitigated by expanding the 
programme to include maternal testing at delivery and at immunisation clinic visits as we pursue the elimination of mother-to-
child transmission.
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In order to identify HIV-infected women 
and offer antiretroviral (ARV) prophylaxis, 
the South African National Prevention of 
Mother-To-Child Transmission (PMTCT) 
of HIV programme recommends 2 HIV tests 
during pregnancy: at the first antenatal visit and at 32 weeks of 
gestation.[1] We present two cases that suggest that additional 
HIV testing strategies are needed to help eliminate the mother-
to-child transmission of HIV.
In a longitudinal study on HIV-exposed infants, we recruited 
infants whose mothers were known to be HIV-infected post 
partum along with a control group of infants born to HIV-
negative women. All women delivering at the Kraaifontein 
Midwife Obstetric Unit were eligible for enrolment. HIV-
exposed infants were matched with HIV-unexposed controls 
within one month of birth. Mother-infant pairs were recruited 
within three days of delivery and a CD4+ T-cell count was 
performed on all women regardless of HIV status. In accordance 
with the study protocol, the infants were reviewed at 2 weeks of 
age and regularly thereafter. At the 2-week visit, the HIV status of 
the uninfected mothers was confirmed with an HIV rapid assay 
using finger-prick blood (Alere Determine HIV 1/2).
Recently, HIV infection was identified on the rapid tests at 
the 2-week visit in 2 women (Table 1). According to antenatal 
clinic documentation, both tested negative during pregnancy: 
at booking (at 21 weeks and 28 weeks of gestation, respectively) 
and at 32 weeks of gestation, as recommended in the national 
guideline.[1] Neither infant was born before 38 weeks of 
gestation. The HIV rapid assay in use in the antenatal clinic at 
the time was the First Response HIV1-2-0 Card Test (Premier 
Medical Corporation Ltd, India). According to policy, only a 
single test is required to screen for HIV. Positive screening tests 
are confirmed with a second rapid assay (ABON HIV 1/2/0 
Tri-Line HIV Rapid Test Device).
Both women elected to breastfeed, although one mother 
switched to infant formula after one week owing to poor feeding. 
Her CD4+ T-cell count at delivery was 680 x 106 cells/l. Her 
infant was symptomatic at age 2 weeks and was immediately 
hospitalised, requiring transfer to the intensive care unit. An 
HIV DNA polymerase chain reaction (PCR) test (Amplicor 
HIV-1 DNA prototype assay 1.5) at 2 weeks was positive.
The CD4+ count of the second woman was 157 x 106 cells/l 
at delivery. Her baby was well and the HIV DNA PCR at 2 
weeks was negative. Daily nevirapine (NVP) for the infant 
was initiated and the mother was referred for combination 
antiretroviral therapy (cART) which was commenced within 
2 weeks. 
Discussion
These two cases raise concerns about antenatal HIV screening 
and the implications for vertical transmission. As expected, 
neither woman received any ARV prophylaxis. 
A recent Medical Research Council (MRC) report on the 
effectiveness of the national PMTCT programme in South 
Africa[2] demonstrated that, among mothers who reported 
being HIV-negative, 4.1% had infants who were HIV-exposed 
at 4 - 8 weeks (measured by the presence of HIV antibodies in 
the infants’ blood). A 2007 surveillance study in KwaZulu-Natal 
(KZN) found that 6.9% of infants whose mothers reported a 
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presence of HIV antibodies in the infants’ 
blood).[3] Of concern is that the vertical 
transmission rate in this group was high (31% 
v. an overall rate of 20.2% at that time).
It is possible that some women knew, but did 
not admit their HIV-positive status. However, 
the KZN study was anonymous, and the MRC 
report demonstrated a high uptake of HIV 
testing and disclosure, making it unlikely that 
this scenario contributed significantly to the 
observations.[2,3] Moreover, the two subjects 
described here each had HIV-negative results 
for rapid tests on two different occasions.
Alternatively, there may have been a 
problem with the HIV rapid antibody assay, 
including that the tests were conducted within 
the window period. Antibodies to HIV can 
be detected at 2 - 3 weeks after infection 
by fourth-generation laboratory enzyme-
linked immunosorbent assay (ELISA) 
tests, which detect both antibody to HIV 
and p24Ag (Fiebig stage II and III). [4] The 
third-generation rapid tests have a window 
period of three to four weeks post infection 
(Fiebig stage III).[4,5] Testing during this 
time will yield a false-negative result. The 
reported sensitivity and specificity of the First 
Response HIV 1-2-0 Card Test are 100% 
and 98.8% when used correctly[5] within the 
WHO recommended range of >98%.[6] In 
our subjects, this explanation could only 
apply to the second assay at 32 weeks, and 
would indicate recent acquisition of infection. 
The rapid assay may have recorded a false-
negative result for the second test. All batches 
of rapid tests are validated by the National 
Institute for Communicable Diseases (NICD) 
on a panel of laboratory samples, but they 
have not been validated in pregnant women 
specifically or in the field. Assay sensitivities 
have been reported between 87% to 95% in 
clinics depending on the product.[2,7] More 
data are therefore required to assess and 
validate HIV rapid assays in pregnant women, 
and to ensure the quality of testing at clinic 
level. Importantly, there is no quality-control 
procedure for negative rapid tests.
The most likely explanation for our findings 
is true acquisition of HIV during pregnancy 
and breastfeeding. Pregnancy poses an 
increased risk for HIV acquisition by women, 
even after adjustment for behavioural and 
other factors; it is possible that the hormonal 
and other biological changes associated with 
pregnancy play a role.[8] High viral loads 
during primary HIV infection increase the 
risk of vertical transmission in utero, peri 
partum and post partum,[9,10] especially in 
the absence of ARV prophylaxis. In studies 
in Botswana and SA, new mothers with 
negative HIV test results or of unknown 
HIV status were tested immediately post 
partum or at infant immunisation visits. 
The results demonstrated a seroconversion 
rate of 2.4 - 7.9% during pregnancy and post 
partum. [2,7,11,12] These women are at high risk 
of vertical transmission.[13-15] In addition, 
they are more likely to use mixed feeding 
practices, placing their infants at greater 
risk for HIV infection. [2,16-18] ‘Mixed feeding’ 
refers to the use of breast milk in addition 
to other fluids (infant formula, water, tea) 
for infant feeding. The increased incidence 
of mixed feeding observed in these women 
is presumably because, having tested HIV-
negative, they perceive no risk.
Repeat HIV testing of mothers during 
late pregnancy, at delivery or at the clinic 
immunisation visits, would identify women 
who acquire HIV during pregnancy and in the 
early post-partum period. The HIV diagnosis 
of infants whose mothers tested negative during 
pregnancy is often delayed,[18] with significant 
implications for morbidity and mortality.[19] 
Most SA women deliver at a healthcare facility[20] 
and 99% attend the 6-week vaccination visit.[2] 
Moreover, testing at these time-points shows 
high uptake,[11,21,22] while offering HIV tests to 
both partners may identify discordant couples 
and allow counselling on HIV prevention.[2] A 
proviso to this is increasing evidence that, even 
within discordant partnerships, a significant 
number of new HIV infections arise from 
extra-couple transmission.[23]
Conclusion
While the elimination of mother-to-child 
transmission of HIV is feasible, it will require 
a modification of current protocols/guidelines 
to include repeat HIV testing of women at 
delivery and/or post partum, a quality-control 
strategy for laboratory testing of a small 
percentage of negative rapid tests, involvement 
of male partners in testing and counselling, 
and an emphasis on exclusive feeding 
practices, regardless of HIV status.
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test at 2 
weeks
1 29 21 21 32 31/10/2012 680 Breast Positive
2 23 28 28 32 05/11/2012 157 Breast Negative
ANC = antenatal clinic visit; PCR = polymerase chain reaction.
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